Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Heterogeneous response of airway eosinophilia to anti-IL-5 biologics in severe asthma patients
Authors:Kopač, Maruša (Author)
Rijavec, Matija (Author)
Korošec, Peter (Author)
Bidovec, Urška (Author)
Kern, Izidor (Author)
Vantur, Romana (Author)
Škrgat, Sabina (Author)
Tipology:1.01 - Original Scientific Article
Organisation:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Many questions concerning responders (R) and nonresponders (NR) in severe eosinophilic asthma (SEA) after blocking the IL-5 (interleukin 5) pathway are still not clear, especially regarding the early parameters of response to biologics in personalized treatment strategies. We evaluated 17 SEA patients treated with anti-IL-5 biologics (16 patients mepolizumab, one patient benralizumab) before the introduction of biologics, and at a week 16 follow-up. Clinical, cellular and immunological parameters in peripheral blood were measured in R and NR. Sputum induction with the measurement of cellular and immunological parameters was performed at 16 weeks only. There were 12 R and 5 NR to biologics. After 16 weeks, there was a significant improvement in percentages of FEV1 (p = 0.001), and asthma control test (ACT) (p = 0.001) in the R group, but not in NR. After 16 weeks, the eosinophils in induced sputum were 27.0% in NR and 4.5% in R (p = 0.05), with no difference in IL-5 concentrations (p = 0.743). Peripheral eosinophilia decreased significantly in NR (p = 0.032) and R (p = 0.002). In patients with SEA on anti-IL-5 therapy, there was a marked difference in airway eosinophilic inflammation between R and NR already at 16 weeks, after anti-IL-5 introduction.
Year of publishing:2022
COBISS_ID:92821507 Link is opened in a new window
ISSN on article:2075-4426
DOI:10.3390/jpm12010070 Link is opened in a new window
Note:Nasl. z nasl. zaslona; Maruša Kopač Šokić in Matija Rijavec sta enakovredna prva avtorja; Opis z dne 11. 1. 2022; Članek št. 70;
Files:.pdf PDF - Presentation file, download (805,99 KB)
URL URL - Source URL, visit
Journal:J. pers. med.
Rights:© 2022 by the authors
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


License:CC BY 4.0, Creative Commons Attribution 4.0 International
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:07.01.2022